TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Examination of the Efficacy, Safety, and Gender Differences in Using Varenicline as an Aid to Smoking Cessation in a Population of Methadone Maintained Opioid Dependent Patients (Pilot Trial)
Brief Summary: The main hypotheses guiding the study are:

1. Stable methadone maintenance patients receiving varenicline will be more likely to maintain abstinence than patients receiving placebo
2. There will be no differences in the type and number of symptoms reported between stable methadone maintenance patients receiving varenicline and placebo
3. There will be no changes in methadone dosage between abstinent and non-abstinent smokers
4. There will be no differences in efficacy, withdrawal symptoms, and safety of varenicline between male and female participants


Options:
A: Arm Label: Varenicline & nicotine patches; Type: EXPERIMENTAL; Interventions: Drug: Varenicline, Drug: Nicotine patches | Arm Label: Varenicline & placebo patches; Type: PLACEBO_COMPARATOR; Interventions: Drug: Varenicline, Drug: Placebo (nicotine patches) | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline & nicotine patches, Varenicline & placebo patches | Intervention Type: DRUG; Name: Nicotine patches; Assigned to Arm(s): Varenicline & nicotine patches | Intervention Type: DRUG; Name: Placebo (nicotine patches); Assigned to Arm(s): Varenicline & placebo patches
B: Arm Label: Active bupropion + counseling; Type: ACTIVE_COMPARATOR; Interventions: Drug: Active bupropion + counseling | Arm Label: Active bupropion , No counseling; Type: ACTIVE_COMPARATOR; Interventions: Drug: Active bupropion, No counseling | Arm Label: Placebo medication + counseling; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo medication + counseling | Arm Label: Placebo medication, No counseling; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo medication, No counseling | Intervention Type: DRUG; Name: Active bupropion + counseling; Assigned to Arm(s): Active bupropion + counseling | Intervention Type: DRUG; Name: Active bupropion, No counseling; Assigned to Arm(s): Active bupropion , No counseling | Intervention Type: DRUG; Name: Placebo medication + counseling; Assigned to Arm(s): Placebo medication + counseling | Intervention Type: DRUG; Name: Placebo medication, No counseling; Assigned to Arm(s): Placebo medication, No counseling
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
D: Arm Label: Varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline, Behavioral: Counseling | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Counseling | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: BEHAVIORAL; Name: Counseling; Assigned to Arm(s): Placebo, Varenicline

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Examination of the Efficacy, Safety, and Gender Differences in Using Varenicline as an Aid to Smoking Cessation in a Population of Methadone Maintained Opioid Dependent Patients (Pilot Trial)
Brief Summary: The main hypotheses guiding the study are:

1. Stable methadone maintenance patients receiving varenicline will be more likely to maintain abstinence than patients receiving placebo
2. There will be no differences in the type and number of symptoms reported between stable methadone maintenance patients receiving varenicline and placebo
3. There will be no changes in methadone dosage between abstinent and non-abstinent smokers
4. There will be no differences in efficacy, withdrawal symptoms, and safety of varenicline between male and female participants


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Chantix, Behavioral: Standard Counseling | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Chantix, Behavioral: Adherence Counseling, Behavioral: Standard Counseling | Intervention Type: DRUG; Name: Chantix; Assigned to Arm(s): 1, 2 | Intervention Type: BEHAVIORAL; Name: Adherence Counseling; Assigned to Arm(s): 2 | Intervention Type: BEHAVIORAL; Name: Standard Counseling; Assigned to Arm(s): 1, 2
B: Arm Label: Group I (varenicline and placebo); Type: EXPERIMENTAL; Interventions: Other: Placebo, Other: Tobacco Cessation Counseling, Drug: Varenicline | Arm Label: Group II (placebo, nicotine patch and lozenge); Type: PLACEBO_COMPARATOR; Interventions: Drug: Nicotine Lozenge, Drug: Nicotine Patch, Other: Placebo, Other: Tobacco Cessation Counseling | Intervention Type: DRUG; Name: Nicotine Lozenge; Assigned to Arm(s): Group II (placebo, nicotine patch and lozenge) | Intervention Type: DRUG; Name: Nicotine Patch; Assigned to Arm(s): Group II (placebo, nicotine patch and lozenge) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Group I (varenicline and placebo), Group II (placebo, nicotine patch and lozenge) | Intervention Type: OTHER; Name: Tobacco Cessation Counseling; Assigned to Arm(s): Group I (varenicline and placebo), Group II (placebo, nicotine patch and lozenge) | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Group I (varenicline and placebo)
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of PEGylated Interferon Beta-1a (BIIB017) in Subjects With Relapsing Multiple Sclerosis
Brief Summary: The primary objective of this study is to determine the efficacy of peginterferon beta-1a in reducing the annualized relapse rate (ARR) in participants with relapsing multiple sclerosis (RMS) at 1 year. The secondary objectives of this study are to determine whether peginterferon beta-1a, at 1 year when compared with placebo, is effective in reducing the total number of new or newly enlarging T2 hyperintense lesions on brain magnetic resonance imaging (MRI) scans, reducing the proportion of participants who relapse, and slowing the progression of disability.


Options:
A: Arm Label: Fingolimod (FTY720) 1.25 mg/day; Type: EXPERIMENTAL; Interventions: Drug: FTY720 | Arm Label: Placebo/Fingolimod (FTY720); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Fingolimod (FTY720) 5.0 mg/day; Type: EXPERIMENTAL; Interventions: Drug: FTY720 | Intervention Type: DRUG; Name: FTY720; Assigned to Arm(s): Fingolimod (FTY720) 1.25 mg/day, Fingolimod (FTY720) 5.0 mg/day | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo/Fingolimod (FTY720)
B: Arm Label: Teriflunomide 7 mg / 14 mg; Type: EXPERIMENTAL; Interventions: Drug: Teriflunomide | Arm Label: Teriflunomide 14 mg / 14 mg; Type: EXPERIMENTAL; Interventions: Drug: Teriflunomide | Arm Label: IFN-β-1a / 14 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Interferon β-1a, Drug: Teriflunomide | Intervention Type: DRUG; Name: Interferon β-1a; Assigned to Arm(s): IFN-β-1a / 14 mg | Intervention Type: DRUG; Name: Teriflunomide; Assigned to Arm(s): IFN-β-1a / 14 mg, Teriflunomide 14 mg / 14 mg, Teriflunomide 7 mg / 14 mg
C: Arm Label: Interferon Beta-1a; Type: ACTIVE_COMPARATOR; Interventions: Biological: Interferon beta-1a | Arm Label: Alemtuzumab 12 mg; Type: EXPERIMENTAL; Interventions: Biological: Alemtuzumab 12 mg | Arm Label: Alemtuzumab 24 mg; Type: EXPERIMENTAL; Interventions: Biological: Alemtuzumab 24 mg | Intervention Type: BIOLOGICAL; Name: Interferon beta-1a; Assigned to Arm(s): Interferon Beta-1a | Intervention Type: BIOLOGICAL; Name: Alemtuzumab 12 mg; Assigned to Arm(s): Alemtuzumab 12 mg | Intervention Type: BIOLOGICAL; Name: Alemtuzumab 24 mg; Assigned to Arm(s): Alemtuzumab 24 mg
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: BIIB017 (peginterferon beta-1a), Drug: Placebo | Arm Label: Peginterferon Beta-1a Q2W; Type: EXPERIMENTAL; Interventions: Drug: BIIB017 (peginterferon beta-1a) | Arm Label: Peginterferon Beta-1a Q4W; Type: EXPERIMENTAL; Interventions: Drug: BIIB017 (peginterferon beta-1a), Drug: Placebo | Intervention Type: DRUG; Name: BIIB017 (peginterferon beta-1a); Assigned to Arm(s): Peginterferon Beta-1a Q2W, Peginterferon Beta-1a Q4W, Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Peginterferon Beta-1a Q4W, Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of PEGylated Interferon Beta-1a (BIIB017) in Subjects With Relapsing Multiple Sclerosis
Brief Summary: The primary objective of this study is to determine the efficacy of peginterferon beta-1a in reducing the annualized relapse rate (ARR) in participants with relapsing multiple sclerosis (RMS) at 1 year. The secondary objectives of this study are to determine whether peginterferon beta-1a, at 1 year when compared with placebo, is effective in reducing the total number of new or newly enlarging T2 hyperintense lesions on brain magnetic resonance imaging (MRI) scans, reducing the proportion of participants who relapse, and slowing the progression of disability.


Options:
A: Intervention Type: DRUG; Name: Daclizumab (Anti-CD25 Humanized Monoclonal Antibody); Assigned to Arm(s): N/A
B: Arm Label: FTY720D 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: FTY720 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: FTY720D 1.25 mg switch to 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: FTY720 | Intervention Type: DRUG; Name: FTY720; Assigned to Arm(s): FTY720D 0.5 mg, FTY720D 1.25 mg switch to 0.5 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Placebo then Evobrutinib 25 mg QD; Type: EXPERIMENTAL; Interventions: Drug: Placebo, Drug: Evobrutinib | Arm Label: Evobrutinib 25 mg QD; Type: EXPERIMENTAL; Interventions: Drug: Evobrutinib | Arm Label: Evobrutinib 75 mg QD; Type: EXPERIMENTAL; Interventions: Drug: Evobrutinib | Arm Label: Evobrutinib 75 mg BID; Type: EXPERIMENTAL; Interventions: Drug: Evobrutinib | Arm Label: Tecfidera; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tecfidera | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Evobrutinib; Assigned to Arm(s): Evobrutinib 75 mg BID | Intervention Type: DRUG; Name: Evobrutinib; Assigned to Arm(s): Evobrutinib 25 mg QD | Intervention Type: DRUG; Name: Evobrutinib; Assigned to Arm(s): Evobrutinib 75 mg QD | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo, Placebo then Evobrutinib 25 mg QD | Intervention Type: DRUG; Name: Tecfidera; Assigned to Arm(s): Tecfidera | Intervention Type: DRUG; Name: Evobrutinib; Assigned to Arm(s): Placebo then Evobrutinib 25 mg QD
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: BIIB017 (peginterferon beta-1a), Drug: Placebo | Arm Label: Peginterferon Beta-1a Q2W; Type: EXPERIMENTAL; Interventions: Drug: BIIB017 (peginterferon beta-1a) | Arm Label: Peginterferon Beta-1a Q4W; Type: EXPERIMENTAL; Interventions: Drug: BIIB017 (peginterferon beta-1a), Drug: Placebo | Intervention Type: DRUG; Name: BIIB017 (peginterferon beta-1a); Assigned to Arm(s): Peginterferon Beta-1a Q2W, Peginterferon Beta-1a Q4W, Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Peginterferon Beta-1a Q4W, Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-masked, Multicenter, Laser-controlled Phase III Study Assessing the Efficacy and Safety of Ranibizumab (Intravitreal Injections) as Adjunctive and Mono-therapy in Patients With Visual Impairment Due to Diabetic Macular Edema
Brief Summary: CRFB002D2301: The core study was designed to confirm the efficacy and safety of ranibizumab (0.5 mg) as adjunctive therapy when added to laser photocoagulation and/or mono-therapy in patients with visual impairment due to diabetic macular edema.

CRFB002D2301E1: A 24 month open-label extension study for participants who completed the 12 month core study evaluated the long-term safety and efficacy of ranibizumab (0.5 mg) as symptomatic treatment for visual impairment due to diabetic macular edema.


Options:
A: Arm Label: Ranibizumab 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab, Procedure: Laser, Procedure: Sham laser | Arm Label: Ranibizumab 0.5 mg + laser; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab, Procedure: Laser | Arm Label: Laser; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ranibizumab, Procedure: Laser, Drug: Sham to ranibizumab | Intervention Type: DRUG; Name: Ranibizumab; Assigned to Arm(s): Laser, Ranibizumab 0.5 mg, Ranibizumab 0.5 mg + laser | Intervention Type: PROCEDURE; Name: Laser; Assigned to Arm(s): Laser, Ranibizumab 0.5 mg, Ranibizumab 0.5 mg + laser | Intervention Type: PROCEDURE; Name: Sham laser; Assigned to Arm(s): Ranibizumab 0.5 mg | Intervention Type: DRUG; Name: Sham to ranibizumab; Assigned to Arm(s): Laser
B: Arm Label: Ranibizumab 0.3 mg; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab | Arm Label: Ranibizumab 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab | Arm Label: Sham injection/ranibizumab 0.5 mg; Type: SHAM_COMPARATOR; Interventions: Drug: Sham injection | Intervention Type: DRUG; Name: Ranibizumab; Assigned to Arm(s): Ranibizumab 0.3 mg, Ranibizumab 0.5 mg | Intervention Type: DRUG; Name: Sham injection; Assigned to Arm(s): Sham injection/ranibizumab 0.5 mg
C: Intervention Type: DRUG; Name: Triamcinolone, Bevacizumab; Assigned to Arm(s): N/A
D: Arm Label: Cohort with routine OCT monitoring; Type: N/A; Interventions: N/A | Arm Label: Cohort without routine OCT monitoring; Type: N/A; Interventions: N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Saving and Empowering Young Lives in Europe in Israel, Evaluation, Intervention and Prevention
Brief Summary: SEYLE is a health promoting program for adolescents in European schools. Its main objectives are to lead adolescents to better health through decreased risk-taking and suicidal behaviors, to evaluate outcomes of different preventive programs and to recommend effective culturally adjusted models for promoting health of adolescents in different European countries. Because of the significance of the SEYLE program and the importance of suicide research, Israel is honored to take part in this program and be a collaborator in it's implementation and research.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aripiprazole | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aripiprazole | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Aripiprazole; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Aripiprazole; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 3
B: Arm Label: Escitalopram; Type: EXPERIMENTAL; Interventions: Drug: Escitalopram | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Escitalopram; Assigned to Arm(s): Escitalopram | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Fluoxetine, Drug: Citalopram | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Venlafaxine | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: Fluoxetine, Behavioral: Cognitive Behavioral Therapy (CBT), Drug: Citalopram | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Drug: Venlafaxine, Behavioral: Cognitive Behavioral Therapy (CBT) | Intervention Type: DRUG; Name: Fluoxetine; Assigned to Arm(s): 1, 3 | Intervention Type: DRUG; Name: Venlafaxine; Assigned to Arm(s): 2, 4 | Intervention Type: BEHAVIORAL; Name: Cognitive Behavioral Therapy (CBT); Assigned to Arm(s): 3, 4 | Intervention Type: DRUG; Name: Citalopram; Assigned to Arm(s): 1, 3
D: Arm Label: QPR intervention; Type: EXPERIMENTAL; Interventions: Other: QPR: question, persuade and refer (SEYLE) | Arm Label: Awareness program; Type: EXPERIMENTAL; Interventions: Other: QPR: question, persuade and refer (SEYLE) | Arm Label: ProfScreen; Type: EXPERIMENTAL; Interventions: Other: QPR: question, persuade and refer (SEYLE) | Arm Label: Control group; Type: EXPERIMENTAL; Interventions: Other: QPR: question, persuade and refer (SEYLE) | Intervention Type: OTHER; Name: QPR: question, persuade and refer (SEYLE); Assigned to Arm(s): Awareness program, Control group, ProfScreen, QPR intervention

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Clinical Study to Assess the Clinical Tolerability, Feasibility and Effectiveness Under Field Conditions of the Combination of Nifurtimox and Eflornithine (NECT) for the Treatment of T.b.Gambiense Human African Trypanosomiasis (HAT) in the Meningo-encephalitic Stage
Brief Summary: Multicenter, open label, uncontrolled phase IIIb study of therapeutic use of the combination of nifurtimox and eflornithine (NECT) for the treatment of Trypanosoma brucei gambiense human African trypanosomiasis (HAT) in the meningo-encephalitic phase.

Overall objectives:

Assess the clinical tolerability, feasibility and effectiveness of NECT co-administration to treat patients with T.b. gambiense human African trypanosomiasis (HAT) in the meningo-encephalitic phase in actual real-life conditions (regular treatment centers of the National HAT Control Programme, NGO treatment centers).

Primary objective:

* Assess the clinical response of the NECT co-administration under field conditions.

Secondary objectives:

* Assess the incidence and type of adverse events (AE), and the capacity of the treatment centers to deal with these.
* Assess the feasibility of the implementation of the NECT coadministration by the health center.
* Assess the effectiveness of the NECT co-administration at 24\* months after treatment.


Options:
A: Intervention Type: DRUG; Name: Nifurtimox-Eflronithine Combination Treatment (NECT); Assigned to Arm(s): N/A
B: Arm Label: NECT (Nifurtimox Eflornithine Combination Therapy); Type: ACTIVE_COMPARATOR; Interventions: Drug: Nifurtimox, Drug: Eflornithine | Arm Label: Fexinidazole; Type: EXPERIMENTAL; Interventions: Drug: Fexinidazole | Intervention Type: DRUG; Name: Fexinidazole; Assigned to Arm(s): Fexinidazole | Intervention Type: DRUG; Name: Nifurtimox; Assigned to Arm(s): NECT (Nifurtimox Eflornithine Combination Therapy) | Intervention Type: DRUG; Name: Eflornithine; Assigned to Arm(s): NECT (Nifurtimox Eflornithine Combination Therapy)
C: Intervention Type: DRUG; Name: Eflornithine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Nifurtimox; Assigned to Arm(s): N/A
D: Arm Label: Fexinidazole; Type: EXPERIMENTAL; Interventions: Drug: Fexinidazole | Intervention Type: DRUG; Name: Fexinidazole; Assigned to Arm(s): Fexinidazole

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Colorectal Cancer Screening in Average-risk Population: a Multicenter, Randomized Control Trial Comparing Immunochemical Fecal Occult Blood Testing Versus Colonoscopy.
Brief Summary: Aims:

1. To compare the efficacy of biennial immunochemical fecal occult blood test (iFOBT) versus colonoscopy every 10 years for the reduction of colorectal cancer-related mortality at 10 years in average-risk population.
2. To determine the compliance and complications associated with both strategies.

Methods: Multicenter, randomized, controlled study in 8 Spanish regions (Aragón, Canarias, Catalunya, Euskadi, Galicia, Madrid, Murcia and Valencia).

Study groups:

* Group I: iFOBT (OC Sensor®) in one stool sample, followed by colonoscopy when a positive result.
* Group II: colonoscopy.

Sample-size calculation: 27,749 subjects in each study group (total: 55,498).


Options:
A: Arm Label: Fecal occult blood testing; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Immunochemical fecal occult blood test | Arm Label: Colonoscopy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Colonoscopy | Intervention Type: PROCEDURE; Name: Immunochemical fecal occult blood test; Assigned to Arm(s): Fecal occult blood testing | Intervention Type: PROCEDURE; Name: Colonoscopy; Assigned to Arm(s): Colonoscopy
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Device: simulator training | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Device: simulator training | Intervention Type: DEVICE; Name: simulator training; Assigned to Arm(s): 1, 2
C: Arm Label: Curriculum Group; Type: EXPERIMENTAL; Interventions: Behavioral: Curriculum Group | Arm Label: Self-directed learning group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Self-directed learning group | Intervention Type: BEHAVIORAL; Name: Curriculum Group; Assigned to Arm(s): Curriculum Group | Intervention Type: BEHAVIORAL; Name: Self-directed learning group; Assigned to Arm(s): Self-directed learning group
D: Arm Label: Progressive Group; Type: EXPERIMENTAL; Interventions: Behavioral: Progressive Group | Arm Label: High-Fidelity Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Progressive Group; Assigned to Arm(s): Progressive Group

Answer: A